{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:11:03Z","timestamp":1777936263407,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.beha.2014.04.005","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T10:45:39Z","timestamp":1397385939000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The coagulopathy in acute promyelocytic leukaemia \u2013 What have we learned in the past twenty years"],"prefix":"10.1016","volume":"27","author":[{"given":"Hau C.","family":"Kwaan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth H.","family":"Cull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2014.04.005_bib1","first-page":"514","article-title":"The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment","volume":"156\u2013161","author":"Lo-Coco","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2014.04.005_bib2","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood.V93.10.3167.410k44_3167_3215","article-title":"Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia","volume":"93","author":"Melnick","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib3","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib4","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"de la Serna","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2011.78","article-title":"Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry","volume":"25","author":"Lehmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.04.005_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood.V57.3.518.518","article-title":"Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity","volume":"57","author":"Myers","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.V64.4.791.791","article-title":"Thrombin generation in acute promyelocytic leukemia","volume":"64","author":"Bauer","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1538-7836.2004.00787.x","article-title":"Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia","volume":"2","author":"Tallman","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.beha.2014.04.005_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.1989.tb06311.x","article-title":"The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination","volume":"71","author":"Bennett","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood.V77.9.1949.1949","article-title":"The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia","volume":"77","author":"Sakata","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.1988.tb02432.x","article-title":"Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia","volume":"70","author":"Avvisati","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib12","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.V86.3.1072.1072","article-title":"Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid","volume":"86","author":"Falanga","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1521-6926(03)00059-8","article-title":"Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia","volume":"16","author":"Falanga","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.beha.2008.12.007","article-title":"The coagulopathy of acute promyelocytic leukaemia revisited","volume":"22","author":"Stein","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJM199904013401303","article-title":"Annexin II and bleeding in acute promyelocytic leukemia","volume":"340","author":"Menell","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2014.04.005_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0145-2126(88)90061-6","article-title":"Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors","volume":"12","author":"Stephens","year":"1988","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2014.04.005_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1365-2141.2000.01890.x","article-title":"Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia","volume":"108","author":"Meijers","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib18","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-07-298851","article-title":"Regulation of S100A10 by the PML-RAR-alpha oncoprotein","volume":"117","author":"O'Connell","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1055\/s-0038-1656026","article-title":"Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS)","volume":"77","author":"Watanabe","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.beha.2014.04.005_bib20","first-page":"2","article-title":"Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment","volume":"7","author":"Dombret","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.04.005_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-2007-976168","article-title":"The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia","volume":"33","author":"Tallman","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.beha.2014.04.005_bib22","first-page":"236","article-title":"Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment","volume":"113","author":"Zhao","year":"2000","journal-title":"Chin Med J"},{"key":"10.1016\/j.beha.2014.04.005_bib23","first-page":"1530","article-title":"The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia","volume":"91","author":"Webert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2014.04.005_bib24","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.V91.9.3093","article-title":"The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia","volume":"91","author":"Barbui","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1055\/s-0030-1267045","article-title":"Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia","volume":"36","author":"Kwaan","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.beha.2014.04.005_bib26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00277-013-1676-6","article-title":"Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia","volume":"92","author":"Ma","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2014.04.005_bib27","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/ATVBAHA.112.251157","article-title":"Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase\/myeloid leukemia cell-1 signaling","volume":"32","author":"Ikezoe","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beha.2014.04.005_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000046588","article-title":"Coagulopathy of acute promyelocytic leukemia","volume":"106","author":"Falanga","year":"2001","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.687","article-title":"Abnormalities in hemostasis in acute promyelocytic leukemia","volume":"20","author":"Kwaan","year":"2002","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2014.04.005_bib30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.leu.2401448","article-title":"Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents","volume":"13","author":"Zhu","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.04.005_bib31","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1021\/bi00362a005","article-title":"Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine","volume":"25","author":"Bach","year":"1986","journal-title":"Biochemistry"},{"key":"10.1016\/j.beha.2014.04.005_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1365-2141.2001.03095.x","article-title":"Thrombogenic role of cells undergoing apoptosis","volume":"115","author":"Wang","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib33","first-page":"417","article-title":"Les aspects du syndrome h\u00e9morragique des leuc\u00e9mies; \u00e0 propos de 12 cas de thrombocytop\u00e9nie et d'un cas de fibrinop\u00e9nie","volume":"20","author":"Croizat","year":"1949","journal-title":"Sang"},{"key":"10.1016\/j.beha.2014.04.005_bib34","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.6004\/jnccn.2013.0127","article-title":"Acute myeloid leukemia, version 2.2013","volume":"11","author":"O'Donnell","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.beha.2014.04.005_bib35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1538-7933.2004.00593.x","article-title":"Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin","volume":"2","author":"Kwaan","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.beha.2014.04.005_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0609.1993.tb00144.x","article-title":"Management of acute promyelocytic leukemia","volume":"50","author":"Fenaux","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib37","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood.V75.11.2112.2112","article-title":"Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients","volume":"75","author":"Rodeghiero","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2141.2000.01936.x","article-title":"Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia","volume":"108","author":"Di Bona","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2011.08922.x","article-title":"The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia","volume":"156","author":"Breen","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.23158","article-title":"Bleeding and thrombosis in acute promyelocytic leukemia","volume":"87","author":"Choudhry","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2014.04.005_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2004.11.001","article-title":"Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia \u2013 a single center experience in 34 patients","volume":"116","author":"Dally","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.beha.2014.04.005_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.leukres.2004.04.021","article-title":"Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom","volume":"29","author":"Tallman","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2014.04.005_bib43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000324844","article-title":"Characterization of human late outgrowth endothelial progenitor-derived cells under various flow conditions","volume":"48","author":"Mazzolai","year":"2011","journal-title":"J\u00a0Vasc Res"},{"key":"10.1016\/j.beha.2014.04.005_bib44","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00277-012-1597-9","article-title":"Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group","volume":"92","author":"Lengfelder","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2014.04.005_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B","article-title":"Acute promyelocytic leukemia in 57 previously untreated patients","volume":"55","author":"Cordonnier","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.04.005_bib47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0002-9343(86)90617-0","article-title":"Acute promyelocytic leukemia. M.D. Anderson Hospital experience","volume":"80","author":"Kantarjian","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.beha.2014.04.005_bib48","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood.V73.5.1116.1116","article-title":"Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital","volume":"73","author":"Cunningham","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib50","first-page":"1113","article-title":"Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage","volume":"8","author":"Hashimoto","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.04.005_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2257.1996.tb00739.x","article-title":"Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin","volume":"18","author":"Mahendra","year":"1996","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib52","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2141.2000.02270-8.x","article-title":"All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia","volume":"110","author":"Brown","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/10428194.2011.605189","article-title":"Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia","volume":"53","author":"Nosari","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2014.04.005_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0609.2004.00237.x","article-title":"Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia","volume":"72","author":"Zver","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib55","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ajh.20713","article-title":"Use of Novoseven for arsenic trioxide-induced bleeding in PML","volume":"81","author":"Alimoghaddam","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2014.04.005_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2169\/internalmedicine.52.7978","article-title":"Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution","volume":"52","author":"Kawano","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.beha.2014.04.005_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.beha.2014.04.005_bib58","first-page":"101","article-title":"Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution","volume":"51","author":"Kawano","year":"2011","journal-title":"J\u00a0Clin Exp Hematol"},{"key":"10.1016\/j.beha.2014.04.005_bib59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0609.2006.00803.x","article-title":"Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome","volume":"78","author":"Yanada","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib60","first-page":"372","article-title":"Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia","volume":"7","author":"Archimbaud","year":"1993","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2014.04.005_bib61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000204581","article-title":"The role of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia","volume":"89","author":"Fenaux","year":"1993","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.leu.2404377","article-title":"Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features","volume":"21","author":"Breccia","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.04.005_bib63","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/ajcp\/92.3.366","article-title":"Hepatic vein thrombosis (Budd-Chiari syndrome) in the microgranular variant of acute promyelocytic leukemia","volume":"92","author":"Riccio","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2014.04.005_bib64","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood.V86.9.3535.bloodjournal8693535","article-title":"Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia","volume":"86","author":"De Stefano","year":"1995","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2014.04.005_bib65","first-page":"1503","article-title":"Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA 96 and LPA 99 protocols","volume":"108","author":"Montesinos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.04.005_bib66","doi-asserted-by":"crossref","first-page":"e2011059","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the PETHEMA group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.beha.2014.04.005_bib67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/ejh.12087","article-title":"Increased risk of central venous catheter-associated thrombosis in acute promyelocytic leukemia: a single-institution experience","volume":"90","author":"Grisariu","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2014.04.005_bib68","doi-asserted-by":"crossref","first-page":"1290e1","DOI":"10.1016\/j.ajem.2013.03.038","article-title":"Acute promyelocytic leukemia; early diagnosis is the key to survival","volume":"31","author":"Roldan","year":"2013","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.beha.2014.04.005_bib69","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/ATVBAHA.111.242859","article-title":"Neutrophil extracellular trap (NET) impact on deep vein thrombosis","volume":"32","author":"Fuchs","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beha.2014.04.005_bib70","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvr028","article-title":"Epigenetic control of tissue-type plasminogen activator synthesis in human endothelial cells","volume":"90","author":"Dunoyer-Geindre","year":"2011","journal-title":"Cardiovasc Res"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T18:47:28Z","timestamp":1597690048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692614000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1521692614000231"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2014.04.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The coagulopathy in acute promyelocytic leukaemia \u2013 What have we learned in the past twenty years","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2014.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}